University of California San Diego researchers have discovered the enzyme responsible for chromothripsis, a process in which a single chromosome is shattered into pieces and rearranged in a scrambled ...
By designing a squaric acid amide that binds a new site on ATP synthase, researchers created PRP020, a potential therapy for ...
Researchers at the Department of Cell and Molecular Biology, Karolinska Institutet have captured the first detailed molecular ...
A quick revision guide covering key concepts, biomolecules, cell organelles, and essential NEET-style MCQs to boost exam ...
Structure's aleniglipron elicited over 11% weight loss in a Phase II trial, sending the biotech's stock up nearly 103% as ...
Clinical Trials Arena on MSN
Structure Therapeutics announces positive results from aleniglipron trial
Structure Therapeutics has reported positive topline results from the ACCESS clinical programme for its investigational oral ...
3d
Novel compound attacks tuberculosis bacteria's ATP synthase, showing promise against drug resistance
Researchers at Martin Luther University Halle-Wittenberg (MLU) have developed a promising new substance for targeting ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related ...
That’s the big idea behind Zymosense, “The Nanoassay Company,” a startup that’s spinning off technology developed in the lab ...
Researchers at Martin Luther University Halle-Wittenberg (MLU) have developed a promising new substance for targeting bacteria that cause tuberculosis. The team have produced a compound that inhibits ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback